Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Norepinephrine in Trauma with Hemorrhagic Shock
NCT06977659Phase 2Enrolling by invitation
- Start
- May 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hemorrhagic shock comparing Norepinephrine with Placebo (2 arms). Primary endpoint: 24-hour mortality. Started May 2025; status: enrolling by invitation.
02
Drugs
norepinephrine
03
Conditions
hemorrhagic shock
Beyond the preview
Go deeper on NCT06977659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06977659.